{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:50:41Z","timestamp":1773985841794,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Incorporating dengue vaccination into existing childhood vaccination programs could increase vaccine coverage. This study assessed the safety and immunogenicity of concomitant versus sequential administration of the combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and the tetravalent dengue vaccine (CYD-TDV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This phase IIIb, randomized, open-label, multicenter study was conducted in the Philippines in individuals 9\u2013\u226460 years of age (NCT02992418). Participants were to receive 3 CYD-TDV doses 6 months apart, the first dose administered either concomitantly or sequentially (28 days post-Tdap). Antibody levels were measured at baseline and 28 days post-first doses of Tdap vaccine and CYD-TDV, using enzyme-linked immunosorbent assay (pertussis, tetanus), micrometabolic inhibition test-toxin neutralization assay (diphtheria) and plaque reduction neutralization test (dengue). Immunogenicity was assessed for all participants, and statistical analysis reported for baseline dengue seropositive participants. Safety was assessed throughout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 688 randomized participants, 629 (91.4%) were baseline dengue seropositive (concomitant group, n = 314 and sequential group, n = 315). After the first dose, non-inferiority of immune responses between concomitant and sequential vaccination was achieved; between-group geometric mean antibody concentration ratios were close to 1 for anti-PT, anti-FHA, anti-PRN and anti-FIM, between-group differences in percent achieving seroprotection (titers \u22650.1 IU\/mL) were 0.26% (diphtheria) and 0.66% (tetanus), and between-group geometric mean antibody titer ratios were close to 1 for dengue serotypes 1\u20134. Safety profiles in both study groups were comparable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>CYD-TDV and Tdap vaccine administered concomitantly or sequentially in baseline dengue seropositive participants elicited comparable immunogenicity and safety profiles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003220","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T01:01:51Z","timestamp":1623459711000},"page":"856-863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine"],"prefix":"10.1097","volume":"40","author":[{"given":"Jaime","family":"Santos","sequence":"first","affiliation":[{"name":"Philippine Children\u2019s Medical Center, Quezon City, The Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Emmeline","family":"Montellano","sequence":"additional","affiliation":[{"name":"Far Eastern University Nicanor Reyes Medical Foundation, Quezon City, The Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rontgene","family":"Solante","sequence":"additional","affiliation":[{"name":"Medical Center Manila, Manila, The Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Perreras","sequence":"additional","affiliation":[{"name":"Research Institute for Tropical Medicine, Alabang Muntinlupa City, The Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Meyer","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myew-Ling","family":"Toh","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Zocchetti","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Vigne","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Mascare\u00f1as","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Mexico City, Mexico."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"R1-20250922","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40249-016-0148-3","article-title":"Outwitting dengue threat and epidemics resurgence in Asia-Pacific countries: strengthening integrated dengue surveillance, monitoring and response systems.","volume":"5","author":"Tambo","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"R2-20250922","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"R3-20250922","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.glohj.2019.06.002","article-title":"Dengue epidemiology.","volume":"3","author":"Jing","year":"2019","journal-title":"Glob J Health"},{"key":"R6-20250922","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue.","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"Lancet"},{"key":"R9-20250922","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"R10-20250922","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America.","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20250922","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"R12-20250922","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy.","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20250922","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018 - Recommendations.","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"R14-20250922","first-page":"433","article-title":"Pertussis vaccines: WHO position paper - September 2015.","volume":"90","year":"2015","journal-title":"Releve epidemiologique hebdomadaire"},{"key":"R18-20250922","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines8010012","article-title":"Safety of co-administration versus separate administration of the same vaccines in children: a systematic literature review.","volume":"8","author":"Bauwens","year":"2019","journal-title":"Vaccines"},{"key":"R20-20250922","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"R21-20250922","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R22-20250922","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/INF.0000000000001542","article-title":"Immunogenicity and safety of a booster injection of DTap-IPV\/\/Hib (Pentaxim) administered concomitantly with tetravalent dengue vaccine in healthy toddlers 15-18 months of age in Mexico: a randomized trial.","volume":"36","author":"Melo","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20250922","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4269\/ajtmh.18-0534","article-title":"Bridging efficacy of a tetravalent dengue vaccine from children\/adolescents to adults in highly endemic countries based on neutralizing antibody response.","volume":"101","author":"Gilbert","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"R24-20250922","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s40265-016-0626-8","article-title":"Tetravalent dengue vaccine: a review in the prevention of dengue disease.","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"R25-20250922","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.vaccine.2011.11.035","article-title":"Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose.","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"R26-20250922","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.vaccine.2008.11.028","article-title":"Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.","volume":"27","author":"Blatter","year":"2009","journal-title":"Vaccine"},{"key":"R27-20250922","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1001\/jama.293.24.3003","article-title":"Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.","volume":"293","author":"Pichichero","year":"2005","journal-title":"JAMA"},{"key":"R28-20250922","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/cei.12822","article-title":"Adult vaccination against tetanus and diphtheria: the European perspective.","volume":"187","author":"Weinberger","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"R29-20250922","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3346\/jkms.2019.34.e31","article-title":"A phase III study to evaluate the immunogenicity and safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in healthy adults.","volume":"34","author":"Lee","year":"2019","journal-title":"J Korean Med Sci"},{"key":"R30-20250922","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.vaccine.2015.03.104","article-title":"Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.","volume":"33","author":"Kovac","year":"2015","journal-title":"Vaccine"},{"key":"R31-20250922","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R32-20250922","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1016\/j.vaccine.2020.07.056","article-title":"Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"R33-20250922","doi-asserted-by":"crossref","first-page":"e0004821","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials.","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"R34-20250922","doi-asserted-by":"crossref","first-page":"e010911","DOI":"10.1136\/bmjopen-2015-010911","article-title":"Safety of Tdap vaccine in pregnant women: an observational study.","volume":"6","author":"Petousis-Harris","year":"2016","journal-title":"BMJ Open"},{"key":"R35-20250922","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jpids\/pix113","article-title":"Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose.","volume":"8","author":"Halperin","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R36-20250922","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/21645515.2016.1234555","article-title":"Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.","volume":"13","author":"Sirivichayakul","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R40-20250922","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1080\/21645515.2019.1581542","article-title":"Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence.","volume":"15","author":"Alderfer","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R41-20250922","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.vaccine.2019.10.092","article-title":"Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: a systematic review and meta-analysis.","volume":"38","author":"Li","year":"2020","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T13:03:05Z","timestamp":1758546185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003220"}},"subtitle":["Randomized Phase IIIb Trial in Healthy Participants 9\u201360 Years of Age in the Philippines"],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003220","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}